- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00716196
A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During Endoscopic Ultrasound (EUS)
September 11, 2012 updated by: Indiana University
A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During EUS
Objective: The purpose of this study was to compare the performance of the monolayer preparation (Cyto Lyt or Thin prep) to the routine use of Papanicolau methods on the analysis of specimens obtained using EUS-FNA.
Study Overview
Status
Completed
Conditions
Detailed Description
Introduction: The presence of a pathologist during an endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is often a luxury.
In addition, preparation of multiple slides for a fine needle aspiration can be time-consuming for the gastroenterologist who waits for verbal feedback on the adequacy of the specimen.
Often, a timely diagnosis is needed to direct patient management.
Currently, there is no established standard of care for EUS-FNA preparation.
A liquid based cytologic fixative preparation (Thin-prep or CytoLyt), is a well-established process used by pathologists for evaluating cervical smears.
It has not yet been adopted or accepted for EUS-FNA.
This method combines multiple aspirates on a single slide, thereby decreasing the number of slides that need to be processed and interpreted by the pathologist
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Clarian/Indiana University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Convenience sample from patients presenting at the GI endoscopy unit for an EUS.
Description
Inclusion Criteria:
- Subjects with known or suspected malignancy (solid mass or lymph node) that are undergoing EUS will be eligible to participate in this study.
- Target lesions such as ascites and cystic lesions will not be considered for this study. However, if a patient has an abnormal solid lesion and abnormal lymph node in addition to the ascites or cystic lesion, they may still be considered for the study. That is, the solid lesions and abnormal lymph nodes are appropriate target lesions for this study.
- No evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol.
- Subject must provide signed written informed consent.
Exclusion Criteria:
- Subjects that have had a previous EUS-FNA are eligible for this study
- Target lesions such as ascites and cystic lesions will not be considered for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Julia K LeBlanc, MD, MPH, Indiana University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2005
Primary Completion (Actual)
April 1, 2007
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
July 15, 2008
First Submitted That Met QC Criteria
July 15, 2008
First Posted (Estimate)
July 16, 2008
Study Record Updates
Last Update Posted (Estimate)
September 12, 2012
Last Update Submitted That Met QC Criteria
September 11, 2012
Last Verified
September 1, 2012
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Suspected Malignant Lesions
-
BayerCompleted
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Liaocheng... and other collaboratorsRecruitingThe Malignant Lesions and Non-malignant Lesions of Pancreas, Bile Duct, Liver and Lymph NodeChina
-
Ain Shams UniversityCompletedOral Potentially Malignant LesionsEgypt
-
Fayoum UniversityCairo UniversityCompletedOral Potentially Malignant LesionsEgypt
-
Franciscus Gasthuis & Vlietland (Hospital)RecruitingMalignant Breast Tumours | Benign Breast LesionsNetherlands
-
Institute of Oncology LjubljanaCompletedPTEN | Breast Lesions of Uncertain Malignant PotentialSlovenia
-
Duke UniversityTerminatedENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION | Benign and Malignant Mediastinal and Hilar Lymph Nodes Known or Suspected MalignancyUnited States
-
University Hospital OstravaRecruitingLaryngeal Disease | Laryngeal Lesions | Hypopharyngeal Lesions | Suspected Laryngeal Cancer | Suspected Hypopharyngeal Cancer | Proven Laryngeal Cancer | Proven Hypopharyngeal CancerCzechia
-
Portuguese Oncology Institute, CoimbraRecruitingGastric | Esophageal | Premalignant Conditions | Malignant Lesions | DuodenalPortugal
-
Assiut UniversityUnknownEfficacy of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions